PMVK drives hepatocarcinogenesis via SP1 phosphorylation–mediated lipid metabolic reprogramming

Ruiyang Liu, Caini Huang, Zhijie Xu, Fuyuan Xu, Xinyi Wen, Zhiju Zhao, Fei Xiao · 2026

Read PMVK drives hepatocarcinogenesis via SP1 phosphorylation–mediated lipid metabolic reprogramming by Ruiyang Liu, Caini Huang, Zhijie Xu, Fuyuan Xu, Xinyi Wen, Zhiju Zhao, Fei Xiao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13308594.txt.

Description

Ruiyang Liu and co-authors find in 2026 a driver of liver cancer growth in a metabolic enzyme called PMVK, found through a gene screen in tumour cells. PMVK tags the factor SP1 at one site, which helps SP1 grip DNA and team with fat control factors SREBP1 and SREBP2.

That team switches on fresh cholesterol and fatty acid making, which feeds tumour stem traits and spread in their tests. High PMVK in patient tumours tracked with high tagged SP1 and with poor outlook for those patients. Blocking the pair, by genes or by a known SP1 drug, curbed tumour growth in models. The axis offers a fresh drug target for liver cancer.

Catalog record

CREATORRuiyang Liu, Caini Huang, Zhijie Xu, Fuyuan Xu, Xinyi Wen, Zhiju Zhao, Fei Xiao
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE50856
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13308594

Browse the full library · About the Tower of Babel